Viking Therapeutics, Inc.

Viking Therapeutics, Inc.verified

VKTX

Price:

$68.62

Market Cap:

$7.50B

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug...[Read more]

Industry

Biotechnology

IPO Date

2015-04-28

Stock Exchange

NASDAQ

Ticker

VKTX

The PE Ratio as of April 2024 (TTM) for Viking Therapeutics, Inc. (VKTX) is -75.41

According to Viking Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -75.41. This represents a change of 332.96% compared to the average of -17.42 of the last 4 quarters.

Viking Therapeutics, Inc. (VKTX) Historical PE Ratio (quarterly & annually)

How has VKTX PE Ratio performed in the past?

The mean historical PE Ratio of Viking Therapeutics, Inc. over the last ten years is -10.04. The current -75.41 PE Ratio has changed 75.03% with respect to the historical average. Over the past ten years (40 quarters), VKTX's PE Ratio was at its highest in in the December 2014 quarter at 6.20. The PE Ratio was at its lowest in in the March 2014 quarter at -37.65.

Quarterly (TTM)
Annual

Average

-10.04

Median

-8.65

Minimum

-22.39

Maximum

-0.93

Viking Therapeutics, Inc. (VKTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Viking Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 289.80%

Maximum Annual PE Ratio = -0.93

Minimum Annual Increase = -99.33%

Minimum Annual PE Ratio = -22.39

Quarterly (TTM)
Annual
YearPE RatioChange
2023-20.4490.70%
2022-10.7263.01%
2021-6.58-42.00%
2020-11.34-49.36%
2019-22.3912.13%
2018-19.96289.52%
2017-5.13289.80%
2016-1.3141.99%
2015-0.93-41.22%
2014-1.58-99.33%

Viking Therapeutics, Inc. (VKTX) Average PE Ratio

How has VKTX PE Ratio performed in the past?

The current PE Ratio of Viking Therapeutics, Inc. (VKTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-12.58

5-year avg

-14.29

10-year avg

-10.04

Viking Therapeutics, Inc. (VKTX) PE Ratio vs. Peers

How is VKTX’s PE Ratio compared to its peers?

Viking Therapeutics, Inc.’s PE Ratio is less than Intercept Pharmaceuticals, Inc. (-13.55), less than Terns Pharmaceuticals, Inc. (-4.12), less than Akero Therapeutics, Inc. (-8.28), greater than Reata Pharmaceuticals, Inc. (-89.36), less than Madrigal Pharmaceuticals, Inc. (-12.48), less than Sarepta Therapeutics, Inc. (-21.46), less than Hepion Pharmaceuticals, Inc. (-0.19), less than PTC Therapeutics, Inc. (-3.18), less than Axsome Therapeutics, Inc. (-13.68), greater than ImmunoGen, Inc. (-122.93), less than Seres Therapeutics, Inc. (-0.74), less than Day One Biopharmaceuticals, Inc. (-6.60), less than X4 Pharmaceuticals, Inc. (-2.00), less than Inozyme Pharma, Inc. (-4.54), less than Acumen Pharmaceuticals, Inc. (-4.29), less than Mereo BioPharma Group plc (-10.91), less than AVROBIO, Inc. (4.36), less than CohBar, Inc. (-0.23), less than Ocean Biomedical, Inc. (-0.42), less than Enveric Biosciences, Inc. (-0.14), less than Elevation Oncology, Inc. (-4.39),

Build a custom stock screener for Viking Therapeutics, Inc. (VKTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viking Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Viking Therapeutics, Inc. (VKTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Viking Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Viking Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Viking Therapeutics, Inc. (VKTX)?

What is the highest PE Ratio for Viking Therapeutics, Inc. (VKTX)?

What is the 3-year average PE Ratio for Viking Therapeutics, Inc. (VKTX)?

What is the 5-year average PE Ratio for Viking Therapeutics, Inc. (VKTX)?

How does the current PE Ratio for Viking Therapeutics, Inc. (VKTX) compare to its historical average?